(VIANEWS) – BOIRON (BOI.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Drug Manufacturers—Specialty & Generic industry.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| BOIRON (BOI.PA) | €50.20 | 2.19% | 8.13% |
| VETOQUINOL (VETO.PA) | €92.80 | 0.91% | 10.37% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. BOIRON (BOI.PA)
2.19% Forward Dividend Yield and 8.13% Return On Equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.89.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 17.37. Meaning, the purchaser of the share is investing €17.37 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.13%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 1, 2023, the estimated forward annual dividend rate is 1.1 and the estimated forward annual dividend yield is 2.19%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.6%, now sitting on 534.24M for the twelve trailing months.
Volatility
BOIRON’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.47%, a positive 0.01%, and a positive 1.33%.
BOIRON’s highest amplitude of average volatility was 0.47% (last week), 0.43% (last month), and 1.33% (last quarter).
Volume
Today’s last reported volume for BOIRON is 66 which is 99.55% below its average volume of 14720.
More news about BOIRON.
2. VETOQUINOL (VETO.PA)
0.91% Forward Dividend Yield and 10.37% Return On Equity
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
Earnings Per Share
As for profitability, VETOQUINOL has a trailing twelve months EPS of €4.06.
PE Ratio
VETOQUINOL has a trailing twelve months price to earnings ratio of 22.86. Meaning, the purchaser of the share is investing €22.86 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.37%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.2%, now sitting on 539.78M for the twelve trailing months.
More news about VETOQUINOL.
